past
decad
understand
complex
natur
chronic
lung
infect
greatli
expand
past
decad
doubl
life
expect
popul
cf
three
factor
central
improv
effect
antimicrobi
therapi
treatment
strategi
earli
erad
pseudomona
aeruginosa
key
strategi
b
improv
airway
clearanc
techniqu
c
improv
infect
control
techniqu
prevent
spread
organ
highli
virul
patient
cf
especi
burkholderia
cenocepacia
use
broaderspectrum
antimicrobi
see
plethora
emerg
highli
resist
bacteria
fungi
cf
airway
understand
role
organ
chronic
infect
inflamm
poorli
delin
box
past
decad
new
technolog
fig
develop
appli
understand
technolog
includ
nucleic
acid
amplif
techniqu
naat
direct
organ
detect
includ
multiplex
naat
virus
use
dna
sequenc
analysi
organ
identif
molecularli
base
epidemiolog
techniqu
includ
puls
field
gel
electrophoresi
pfge
multilocu
sequenc
type
whole
genom
sequenc
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectroscopi
malditof
ms
perhap
excit
develop
applic
new
technolog
use
direct
sequenc
techniqu
studi
cf
microbiom
studi
hold
promis
new
understand
diseas
process
accompani
improv
treatment
strategi
antimicrobi
era
children
cf
surviv
past
age
year
children
die
primarili
failur
thrive
coupl
bacteri
pneumonia
organ
found
lung
autopsi
children
almost
alway
staphylococcu
aureu
advent
antistaphylococc
antimicrobi
therapi
mortal
caus
aureu
decreas
substanti
continu
predomin
cf
pathogen
birth
adolesc
children
infect
preadolesc
earli
adolesc
improv
antistaphylococc
therapi
especi
use
oral
agent
oral
cephalosporin
trimethoprimsulfamethoxazol
tmpsmx
like
contribut
improv
life
expect
seen
patient
cf
howev
effect
antistaphylococc
therapi
without
cost
three
antimicrobi
resist
issu
arisen
must
consid
care
patient
cf
first
use
oral
tmpsmx
associ
emerg
small
coloni
variant
scv
aureu
resist
mechan
organ
abil
use
thymidin
obtain
environ
bypass
folic
acid
synthesi
pathway
target
tmpsmx
organ
consid
thymidin
depend
organ
fit
wildtyp
organ
grow
slowli
produc
small
streptococcallik
coloni
enrich
media
anoth
scv
seen
aureu
strain
defect
electron
transport
strain
resist
aminoglycosid
mutant
gener
suffici
proton
motor
forc
drive
transport
larg
highli
charg
molecul
bacteri
cytoplasm
scv
less
suscept
infect
patient
cystic
fibrosi
antimicrobi
especi
blactam
slow
growth
rate
make
challeng
treat
result
greater
declin
pulmonari
function
second
resist
problem
patient
cf
problem
methicillinresist
aureu
mrsa
recogn
approxim
patient
cf
mrsa
fig
also
recogn
patient
cf
infect
patient
cystic
fibrosi
necrot
pneumonia
signific
morbid
mortal
excess
seri
concern
organ
would
problem
patient
cf
well
survey
perform
found
approxim
patient
cf
institut
camrsa
recov
respiratori
specimen
approxim
patient
center
chronic
infect
episod
necrot
pneumonia
seen
popul
patient
cf
period
third
antimicrobi
resist
issu
observ
vancomycinintermedi
aureu
visa
mechan
resist
believ
thicken
cell
wall
prevent
vancomycin
reach
site
peptidoglycan
synthesi
screen
aureu
isol
visa
phenotyp
vancomycin
minimum
inhibitori
concentr
mic
mgml
past
year
use
vancomycin
etest
vitek
suscept
test
biomerieux
durham
nc
test
excess
isol
patient
cf
miller
gilligan
p
unpublish
data
found
visa
patient
patient
chronic
infect
mrsa
year
receiv
repeat
cours
vancomycin
time
pulmonari
function
declin
emerg
visa
treat
multipl
cours
linezolid
ceftarolin
neither
success
erad
organ
declin
lung
function
receiv
doubl
lung
transplant
recent
bronchoscopi
cultur
month
transplant
posit
aureu
infect
cultur
organ
vancomycin
oxacillin
suscept
visa
strain
recov
multipl
bronchoscopi
specimen
obtain
posttranspl
period
miller
gilligan
p
unpublish
data
laboratori
detect
identif
aureu
patient
cf
straightforward
patient
often
infect
organ
especi
mucoid
p
aeruginosa
select
media
recoveri
use
two
media
mannitol
salt
agar
fig
chromogen
aureu
agar
effect
recoveri
scv
wildtyp
strain
scv
aureu
typic
morpholog
mannitol
salt
agar
wherea
chromogen
media
organ
may
grow
slowli
give
typic
phenotyp
reaction
organ
identif
straightforward
catalas
latex
agglutin
coagulas
test
highli
accur
malditof
ms
work
well
identif
aureu
patient
cf
although
abil
speciat
scv
report
suscept
test
straightforward
except
detect
visa
strain
isol
accur
method
micbas
method
etest
mic
tend
run
higher
convent
agar
broth
dilut
method
aureu
isol
vancomycin
mic
mgml
greater
confirm
convent
mic
method
key
pathogen
chronic
lung
diseas
unusu
morphotyp
p
aeruginosa
refer
mucoid
organ
typic
obtain
patient
environ
although
patienttopati
spread
virul
clone
occur
pathogenesi
p
aeruginosa
depend
transit
organ
motil
virul
nonmucoid
organ
nonmotil
compar
avirul
mucoid
organ
adapt
live
cf
airway
transit
believ
caus
mutat
inactiv
muca
gene
regul
algin
product
alginateproduc
organ
grow
biofilm
within
mucou
layer
bronchiol
cf
lung
organ
may
observ
microcoloni
mucou
layer
observ
microscop
agar
plate
organ
appear
mucoid
coloni
fig
lung
organ
resist
mechan
clearanc
phagocytosi
antimicrobi
therapi
although
compar
avirul
induc
chronic
inflammatori
respons
believ
respons
lung
damag
result
patient
demis
diseas
process
take
place
period
year
decad
unit
state
adult
infect
organ
longer
patient
remain
free
chronic
infect
p
aeruginosa
longer
life
expect
highli
aggress
antimicrobi
therapeut
approach
first
use
danish
patient
cf
erad
earli
infect
p
aeruginosa
shown
lengthen
time
patient
cf
remain
p
aeruginosa
free
result
danish
patient
cf
perhap
longest
life
expect
cf
popul
world
year
laboratori
diagnosi
infect
organ
easili
accomplish
readili
recov
nonselect
agar
chocol
select
agar
macconkey
select
agar
specif
p
aeruginosa
requir
addit
identif
easili
accomplish
organ
oxidas
posit
mucoid
produc
green
pyoverdin
bluegreen
pyocyanin
pigment
characterist
identifi
least
cf
isol
malditof
ms
shown
accur
identifi
mucoid
nonmucoid
strain
p
aeruginosa
suscept
test
p
aeruginosa
patient
cf
challeng
antimicrobi
suscept
result
use
autom
suscept
system
correl
poorli
refer
method
recommend
rather
disk
diffus
etest
recommend
paradox
unlik
convent
suscept
test
accur
predict
vivo
respons
reason
situat
complex
explain
part
compar
suscept
p
aeruginosa
antimicrobi
organ
grown
convent
manner
plankton
versu
biofilm
mode
growth
p
aeruginosa
grown
biofilm
time
resist
class
blactam
grown
plankton
differ
explain
part
reduc
growth
rate
mucoid
coloni
possibl
antimicrobi
penetr
cell
algin
layer
littl
differ
mic
aminoglcyosid
fluoroquinolon
grown
condit
complic
interpret
result
grow
bodi
literatur
suggest
p
aeruginosa
may
grow
anaerob
condit
behind
mucou
plug
thicken
mucu
airway
tobramycin
activ
anaerob
condit
poor
transport
bacteria
aerosol
tobramycin
therapi
key
strategi
earli
erad
p
aeruginosa
may
act
organ
airway
grow
superfici
layer
mucu
chronic
p
aeruginosa
infect
may
establish
organ
grow
biofilm
anox
portion
mucou
layer
complex
suscept
test
caus
widespread
use
aerosol
antimicrobi
tobramycin
colistin
aztreonam
use
prevent
establish
chronic
p
aeruginosa
suppress
growth
p
aeruginosa
patient
chronic
infect
antimicrobi
suscept
base
achiev
serum
drug
concentr
suscept
test
accur
predict
resist
patient
receiv
aerosol
antimicrobi
reach
airway
level
least
time
greater
serum
level
addit
problem
confront
laboratorian
determin
antimicrobi
suscept
p
aeruginosa
technic
suscept
test
mucoid
p
aeruginosa
poorli
reproduc
oper
depend
late
stage
chronic
p
aeruginosa
infect
mani
round
intraven
aerosol
antimicrobi
therapi
organ
may
becom
resist
class
antimicrobi
one
strategi
perform
multicombin
bactericid
test
mcbt
method
combin
serum
achiev
concentr
place
microtit
well
inocul
bacteria
incub
overnight
subcultur
determin
combin
bactericid
idea
behind
method
give
rational
choos
antimicrobi
combin
would
use
treat
infect
howev
random
doubleblind
control
clinic
trial
perform
compar
mcbt
convent
suscept
outcom
similar
group
although
studi
technic
well
perform
flaw
patient
studi
infect
organ
level
suscept
antimicrobi
would
need
mcbt
base
studi
mcbt
abandon
cf
commun
earli
signific
new
pathogen
call
pseudomona
cepacia
recogn
lung
infect
patient
cf
care
differ
major
cf
center
approxim
patient
cf
organ
caus
fatal
ill
call
cepacia
syndrom
syndrom
patient
respiratori
infect
hallmark
rapid
declin
pulmonari
function
frequent
bacteremia
highli
unusu
find
patient
cf
subsequ
p
cepacia
reclassifi
belong
genu
burkholderia
vandamm
colleagu
show
organ
identifi
burkholderia
cepacia
repres
multipl
speci
bacteria
call
genomovar
b
cepacia
complex
recogn
consist
differ
speci
speci
within
complex
believ
primarili
respons
cepacia
syndrom
b
cenocepacia
although
b
multivoran
b
dolosa
also
associ
b
cenocepacia
b
multivoran
recov
b
cepacia
complex
infect
seen
patient
cf
molecular
epidemiolog
b
cenocepacia
reason
well
understood
three
differ
b
cenocepacia
clone
design
phdc
midwest
associ
initi
descript
b
cepacia
pathogen
patient
cf
clone
spread
person
person
although
mani
patient
uniqu
clone
like
acquir
environ
shown
strain
spread
toronto
europ
predomin
strain
canada
organ
unusu
appendag
call
cabl
pilin
believ
respons
high
transmiss
b
cepacia
b
multivoran
associ
acceler
lung
function
declin
high
mortal
often
panresist
antimicrobi
lung
transplant
believ
lifesav
therapi
patient
earli
molecular
epidemiolog
studi
use
pfge
show
patient
infect
b
cepacia
complex
transplant
highli
antimicrobialresist
strain
b
cepacia
complex
transplant
subsequ
observ
patient
cf
chronic
infect
b
cenocepacia
receiv
lung
transplant
higher
mortal
year
year
transplant
infect
bacteria
earli
posttranspl
period
patient
infect
b
cenocepacia
sepsi
posit
blood
cultur
transplant
complic
wound
dehisc
posttranspl
patient
b
cenocepacia
sepsi
grim
prognosi
survivor
bronchiol
obliteran
addit
problem
seen
patient
popul
studi
also
show
increas
risk
death
transplant
patient
cf
infect
transplant
b
cenocepacia
result
center
longer
transplant
patient
cf
infect
b
cenocepacia
one
difficulti
recov
b
cepacia
respiratori
specimen
patient
cf
organ
grow
slowli
compar
mucoid
p
aeruginosa
consequ
growth
b
cepacia
may
obscur
media
three
differ
group
develop
isol
media
recoveri
b
cepacia
complex
organ
b
cepacia
select
agar
bcsa
superior
b
cepacia
recoveri
compar
p
cepacia
agar
oxidationferment
polymyxinbacitracinlactos
agar
media
contain
polymixin
select
agent
b
cepacia
complex
organ
isol
media
cf
respiratori
specimen
also
larg
group
environment
glucos
nonferment
similar
b
cepacia
also
recov
organ
often
phenotyp
difficult
separ
b
cepacia
use
commerci
avail
kit
result
infect
patient
cystic
fibrosi
misidentif
nonb
cepacia
isol
b
cepacia
complex
one
altern
isol
rel
inert
biochem
make
difficult
identifi
use
commerci
avail
phenotyp
method
misidentif
nonb
cepacia
organ
b
cepacia
grim
consequ
patient
cf
addit
longer
candid
lung
transplant
center
patient
complet
segreg
children
adult
cf
like
differ
clinic
day
must
alway
isol
hospit
mean
trip
playroom
interact
children
may
longer
attend
cf
sponsor
social
function
meet
particip
camp
patient
cf
result
social
isol
individu
potenti
exclus
lifesav
therapi
draconian
measur
success
blunt
spread
organ
among
patient
cf
perhap
importantli
misidentifi
b
cepacia
complex
organ
speci
genera
result
failur
isol
patient
potenti
deadli
organ
spread
patient
cf
cf
burkholderia
gladioli
first
organ
recov
b
cepaciaselect
media
recogn
misidentifi
b
cepacia
use
phenotyp
mean
earli
part
centuri
recogn
ribosom
rna
rrna
sequenc
superior
phenotyp
method
differenti
b
cepacia
complex
organ
genera
grow
b
cepaciaselect
media
b
gladioli
experi
rrna
sequenc
past
year
shown
tabl
except
unusu
p
aeruginosa
phenotyp
identifi
sequenc
rest
organ
identifi
recov
bcsa
b
cepacia
select
medium
use
mani
nonb
cepacia
complex
organ
requir
identif
grow
bcsa
almost
organ
list
tabl
recov
primarili
patient
cf
includ
ralstonia
chyseobacterium
inquilinu
pandoraea
infrequ
recov
believ
limit
clinic
import
one
group
report
laboratori
gramneg
rod
although
publish
data
suggest
role
b
gladioli
patient
cf
except
seem
lung
transplant
recipi
decreas
surviv
compar
transplant
recipi
burkholderia
stenotrophomona
achromobact
spp
recov
frequenc
patient
cf
especi
older
patient
receiv
mani
round
antipseudomon
antimicrobi
speci
subject
next
section
articl
one
problem
rrna
sequenc
identif
accur
differenti
member
b
cepacia
complex
seem
differ
virul
among
differ
speci
within
complex
accur
speciat
import
three
speci
recogn
pathogen
patient
cf
abl
spread
person
person
b
cenocepacia
b
multivoran
b
dolosa
speci
seen
degre
frequenc
patient
popul
includ
b
vietnamienesi
b
cepacia
experi
speci
within
complex
rare
ever
isol
accur
speciat
isol
b
cepacia
complex
accomplish
sequenc
reca
gene
requir
use
sequenc
step
accur
identifi
isol
belong
b
cepacia
complex
time
consum
expens
requir
day
obtain
accur
answer
result
altern
identif
method
sought
promis
malditof
ms
other
shown
malditof
accur
identifi
organ
b
cepacia
complex
differenti
readili
genera
organ
grow
bcsa
importantli
b
gladioli
preliminari
studi
suggest
bruker
system
accur
identifi
b
cenocepacia
isol
vitek
system
system
accur
speciat
b
multivoran
b
vietnamienesi
bruker
system
misidentifi
b
contaminan
primarili
b
cepacia
may
also
misidentifi
b
cenocepacia
b
multivoran
databas
improv
like
major
cf
pathogen
b
cenocepacia
b
multivoran
accur
identifi
system
b
cepacia
complex
one
antimicrobialresist
group
organ
organ
intrins
resist
colistin
aminoglycosid
clinic
laboratori
standard
institut
suscept
breakpoint
exist
ceftazidim
ticarcillinclavulan
acid
tmpsmx
meropenem
minocyclin
fluoroquinolon
although
larg
percentag
isol
may
initi
suscept
agent
resist
develop
time
mani
strain
becom
resist
antimicrobi
agent
complic
treatment
lack
evid
specif
antimicrobi
treatment
regimen
effect
treat
b
cepacia
complex
pulmonari
exacerb
stenotrophomona
achromobact
glucos
nonfer
rod
found
frequent
patient
cf
b
cepacia
complex
organ
stenotrophomona
found
approxim
patient
cf
wherea
achromobact
found
incid
organ
increas
age
like
reflect
patient
multipl
round
antipseudomon
antimicrobi
therapi
clinic
signific
organ
debat
one
studi
suggest
patient
precipit
antibodi
achromobact
antigen
rapid
declin
lung
function
studi
support
notion
achromobact
pathogen
stori
similar
stenotrophmona
patient
may
like
poor
pulmonari
function
may
requir
lung
transplant
clear
whether
organ
repres
marker
sever
lung
diseas
caus
diseas
three
differ
approach
use
identifi
organ
convent
phenotyp
method
rrna
sequenc
malditof
ms
phenotyp
method
work
reason
well
organ
although
greater
confid
use
vitek
stenotrophomona
maltophilia
compar
achromobact
spp
madlitof
ms
accur
identifi
speci
organ
resist
aminoglycosid
may
develop
resist
colistin
addit
stenotrophomona
produc
metalloblactamas
confer
resist
carbapenem
organ
may
initi
suscept
levofloxacin
tmpsmx
develop
resist
time
initi
suscept
achromobact
similar
b
cepacia
complex
suscept
ceftazidim
meropenem
fluoroquinolon
tmpsmx
common
howev
drug
resist
develop
time
panresist
organ
seen
past
year
mycobacteria
recogn
increasingli
import
agent
chronic
lung
infect
patient
cf
although
cultur
patient
cf
mycobacterium
year
institut
never
recov
mycobacterium
tuberculosi
mycobacteri
speci
frequent
associ
infect
nontubercul
mycobacteria
avium
complex
abscessu
complex
increas
bodi
evid
avium
complex
abscessu
complex
caus
chronic
infect
patient
cf
may
respons
declin
pulmonari
function
although
dramat
b
cepacia
p
aeruginosa
addit
patient
popul
infect
avium
complex
seem
older
sever
diseas
infect
abscessu
group
seem
younger
sever
lung
diseas
recent
studi
use
whole
genom
sequenc
suggest
abscessu
group
show
potenti
spread
person
person
cf
center
make
anoth
target
infect
prevent
attempt
recov
nontubercul
mycobacteria
cf
respiratori
specimen
challeng
laboratori
approxim
specimen
contain
p
aeruginosa
resist
nacetyl
sodium
hydroxid
decontamin
standard
method
use
cultur
respiratori
specimen
mycobacteria
contamin
rate
may
seen
use
decontamin
method
cf
respiratori
specimen
second
step
ad
oxal
acid
contamin
rate
reduc
although
low
number
avium
complex
may
recov
chlorohexidin
alon
shown
effect
mean
decontamin
cf
respiratori
specimen
recoveri
nontubercul
mycobacteria
use
observ
concern
recoveri
abscessu
group
organ
observ
group
organ
recov
medium
routin
use
bacteri
isol
specif
bcsa
abscessu
group
clinic
isol
recov
bcsa
infect
individu
wherea
organ
recov
use
mycobacterialspecif
cultur
method
twentyf
percent
patient
cf
abscessu
complex
first
recov
routin
cultur
addit
incub
bcsa
plate
day
greatli
enhanc
recoveri
compar
incub
result
routin
examin
bcsa
plate
presenc
rapidli
grow
mycobacterium
phenotyp
identif
nontubercul
mycobacteria
challeng
particularli
accur
result
use
rrna
sequenc
analysi
identif
organ
rrna
sequenc
work
well
identif
avium
complex
abscessu
complex
isol
distinguish
chelona
result
second
target
need
rpob
use
purpos
use
differenti
abscessu
complex
chelona
whole
genom
sequenc
shown
center
abscessu
subspeci
massilens
predomin
evid
persontoperson
spread
whole
genom
sequenc
abscessu
complex
isol
patient
cf
center
show
abscessu
subspeci
abscessu
predomin
grogono
floto
gilligan
unpublish
antimicrobi
resist
major
problem
nontubercul
mycobacteria
treatment
antim
tuberculosi
therapi
ineffect
organ
complic
treatment
lack
random
control
trial
antimicrobi
treatment
group
organ
suscept
test
use
broth
dilut
help
guid
antimicrobi
choic
suscept
predict
broth
mic
suscept
test
macrolid
abscessu
group
incub
day
detect
induc
macrolid
resist
clarithromycin
seem
potent
induc
resist
azithromycin
make
azithromycin
central
treatment
abscessu
infect
potenti
lifesav
therapi
patient
cf
infect
sever
abscessu
lung
transplant
howev
base
anecdot
experi
case
report
abscessu
complex
infect
contraind
lifesav
procedur
strategi
seem
logic
given
similar
b
cepacia
abscessu
organ
environ
organ
highli
drug
resist
make
difficult
treat
abl
spread
person
person
associ
wound
dehisc
transplant
recent
singlecent
studi
patient
cf
abscessu
receiv
doubl
lung
transplant
show
surviv
rate
control
popul
suggest
organ
contraind
lung
transplant
fungi
long
recogn
role
cf
lung
diseas
particular
fungi
aspergillu
fumigatu
scedosporium
apiospermum
shown
longterm
colon
patient
cf
organ
frequent
associ
allerg
bronchopulmonari
diseas
character
subacut
clinic
diseas
eosinophilia
increas
ige
level
skin
test
reactiv
case
aspergillu
presenc
serum
ige
specif
aspergillu
caus
chest
imag
chang
attribut
bacteri
agent
addit
postlung
transplant
infect
well
describ
organ
although
colon
organ
contraind
lung
transplant
candida
spp
found
mani
patient
cf
especi
select
media
use
patient
cf
receiv
antibacteri
earli
age
presenc
organ
colon
airway
surpris
clinic
signific
candida
patient
cf
clearli
understood
clinician
discount
organ
signific
naat
allow
detect
pneumocysti
jirovecii
airway
patient
cf
prospect
studi
adult
cf
found
pneumocysti
jirovecii
sputum
lung
function
patient
better
without
pneumocysti
jirovecii
patient
like
mild
diseas
free
p
aeruginosa
fungal
agent
recent
emerg
patient
cf
trichosporon
increas
use
antifung
agent
treat
diseas
associ
aspergillu
scedosporium
trichosporon
resist
antifung
amphotericin
echinocandin
may
find
nich
cf
airway
fungemia
caus
trichosporon
report
patient
cf
doubl
lung
transplant
recipi
without
use
select
fungal
medium
found
patient
cf
patient
tend
rapid
declin
lung
function
whether
situat
directli
attribut
trichosporon
infect
unknown
isol
aspergillu
scedosporium
trichosporon
accomplish
media
use
bacteri
isol
highli
select
natur
bcsa
particularli
use
isol
fungi
convent
techniqu
suffici
identif
organ
suscept
test
recommend
mani
year
viral
agent
consid
play
prime
role
initi
step
establish
chronic
lung
infect
howev
almost
data
support
theori
base
serolog
data
cultur
data
support
theori
part
frequent
contamin
viral
respiratori
cultur
especi
patient
infect
p
aeruginosa
advent
naat
test
virus
clearer
pictur
role
virus
like
emerg
well
recogn
acut
exacerb
associ
influenza
respiratori
syncyti
viru
one
interest
observ
high
rate
detect
rhinoviru
approxim
multiplex
polymeras
chain
reaction
use
rhinoviru
tend
persist
cf
airway
viral
load
increas
pulmonari
exacerb
use
cf
airway
epitheli
model
shown
rhinoviru
superinfect
p
aeruginosainfect
cell
caus
releas
plankton
bacteria
releas
plankton
bacteria
viral
infect
may
import
trigger
cf
pulmonari
exacerb
diagnosi
cf
respiratori
viral
infect
revolution
use
naat
naat
diagnost
approv
us
food
drug
administr
avail
influenza
ab
combin
influenza
ab
respiratori
syncyti
viru
rsv
multiplex
naat
adenoviru
coronaviru
influenza
virus
ab
metapneumoviru
parainfluenza
viru
rsv
rhinoviru
evalu
compar
differ
method
specif
patient
cf
reliabl
method
unknown
patient
popul
given
unusu
natur
matrix
viru
may
found
specif
evalu
naat
perform
specimen
would
use
metaanalysi
influenza
antigen
detect
assay
suggest
method
lack
sensit
patient
low
viral
load
evalu
patient
cf
recommend
patient
popul
microbiom
analysi
chang
way
think
chronic
infect
patient
cf
learn
organ
beyond
alreadi
discuss
may
play
import
role
cf
lung
diseas
organ
typic
believ
belong
normal
microflora
oropharynx
prevotella
veillonella
streptococcu
anginosu
group
found
respiratori
tract
patient
cf
specul
organ
might
upregul
downregul
virul
gene
pathogen
p
aeruginosa
obtain
essenti
nutrient
activ
pathogen
anoth
observ
arisen
result
microbiom
studi
microbi
commun
remark
stabl
even
face
repeat
round
antimicrobi
therapi
addit
chronic
p
aeruginosa
infect
establish
divers
microbi
commun
declin
result
p
aeruginosa
apex
predat
cf
airway
microbiom
elimin
competitor
adapt
downregul
virul
gene
allow
longterm
surviv
human
host
next
decad
get
closer
answer
